Related Experiment Video
Updated: Jul 9, 2026
09:01
A Macrophage-Tumor Spheroid Co-Invasion Assay
Published on: January 24, 2025
Macrophage migration inhibitory factor in cancer
Vildan Yasasever1, Hakan Camlica, Derya Duranyildiz
1Department of Basic Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. yasasever@yahoo.com
Cancer Investigation
|December 7, 2007
Summary
Macrophage migration inhibitory factor (MIF) is significantly elevated in colorectal cancer and malignant melanoma patients. This finding suggests MIF
Area of Science:
- Oncology
- Immunology
Background:
- Macrophage migration inhibitory factor (MIF) plays a role in immune regulation.
- Elevated MIF levels are implicated in various cancers.
Purpose of the Study:
- To investigate macrophage migration inhibitory factor (MIF) expression in colorectal cancer (CRC) and malignant melanoma (MM).
- To assess the diagnostic potential of MIF in these cancers.
Main Methods:
- Serum MIF concentrations were measured using enzyme-linked immunosorbent assay (ELISA).
- Study included 63 CRC patients, 65 MM patients, and 25 healthy controls.
- Diagnostic sensitivity and specificity of MIF were calculated.
Main Results:
- Serum MIF levels were significantly higher in both CRC (p < 0.001) and MM (p = 0.032) patients compared to controls.
- Colorectal cancer patients exhibited particularly high expression and secretion of MIF.
- MIF demonstrated potential diagnostic utility for both cancer types.
Conclusions:
- MIF is significantly upregulated in colorectal cancer and malignant melanoma.
- Elevated serum MIF may serve as a biomarker for diagnosing these malignancies.
- Further research is warranted to explore MIF's role in cancer progression and as a therapeutic target.
